total, with COPD, of all stages, who were hospitalized in the pneumonology department, in 2006 and 2007. The analysis was performed retrospectively. Information on mean treatment cost per patient is presented separately for the I-IV COPD stages, according to GOLD criteria. Direct cost analysis was based on cost of personnel of the clinic, medication, laboratory and imaging tests. The economic analysis did not include the depreciation of capital assets as well as the overhead cost. The prices used for the analysis were based on Greek NHS prices (FEK157/91, A' issue), 2006 Euros. RESULTS: The mean (SD) length of stay in the deparment of pneumonology for a COPD patient was 6 (4) days and the mean(SD) actual cost per patient with stage I COPD was €1091 (85), the mean cost for a patient with stage II COPD was estimated at €1081 (106.5) for the the whole length of stay and the mean cost for stage III and IV COPD patients are 1146 (120,3) and €1222 (197), respectively. CONCLUSIONS: COPD posses a considerable economic burden to health care systems and societies. These findings are in accordance to international literature.
Jahnz-Rózyk K, Targowski T, Mierzejewska MJ, From S Military Institute of Health Service, Warsaw, Poland OBJECTIVES: Assessment of direct and indirect costs of COPD exacerbations under usual clinical practice in primary and secondary care from societal perspective in Poland METHODS: An observational, prospective study was conducted among patients with exacerbation of moderate or severe COPD. All patients (n = 197) were divided into two groups depending on place of care. The group treated in hospital care (HC) and in ambulatory care (AC) adequatly oconsisted of 89 and 108 patients. The direct costs included cost of drugs, diagnostic tests, inhospital and outpatient care. We singled out one-day medical treatment facility costs for inpatients. The indirect costs included costs of work days lost. RESULTS: The mean duration of COPD exacerbation did not differ significantly between the groups (p > 0.5, adaquately 9.5 and 8.8 days for HC and AC group). The total health care cost per exacerbation was €1410,0 (5078.50 PLN) in secondary care (the HC group) and it was 10.5 times higher than the total cost of exacerbation in primary care (the AC group) €134,3 (483.80 PLN) (according to course of currencies on 15 December 2007). The costs of drugs and diagnostic tests were significantly higher in the HC group than in the AC group, however it were facility costs of inhospital stay and medical visits in the HC group that influenced expenditures related to COPD exacerbations most tremendously, as they were 27 times higher than in the AC group. CONCLUSIONS: In Poland the costs of COPD exacerbation managed in secondary care are 10.5-fold higher than in primary care. Therefore, the decisions about admission of patients with COPD exacerbation to hospital should be made carefully. Multivariate methods were used to adjust for differences in potential confounders across treatment groups, such as patient age, gender, COPD severity score, Charlson comorbidity score, prescribing physician specialty, patterns of other respiratory drug use, and geographic region. Given the eminent ban (effective January 1, 2009) on MDIs using CFC propellant, in addition to actual claims payments, hypothetical "HFA-propellant-only" claims payments, calculated by replacing payment rates for CFC drugs with payment rates for HFA versions of the same drugs, also are analyzed to enhance the applicability of study results to the post-CFC environment. RESULTS: Total payments for LEV patients were $2769 higher (p < 0.001) compared to ALB patients. Total payments for LEV patients were $2467 higher (p < 0.001) than hypothetical ALB-HFA-only patients. Payments for respiratory drugs were higher for LEV patients ($673, p < 0.001; projected HFA-only payments $515; p < 0.001). There was no statistically significant difference between ALB and LEV patients in risk of hospitalization (OR = 1.033, p = 0.56) or frequency of ED visits (IRR = 0.99, p = 0.80). However, LEV patients had a higher frequency of total outpatient visits (IRR = 1.13, p < 0.001) and COPD-related outpatient visits (IRR = 1.17, p < 0.001). CONCLUSIONS: COPD patients using LEV had higher total payments and respiratory drug payments compared to ALB patients. LEV patients had more frequent outpatient visits. There was no consistent, statistically significant association between treatment and either likelihood or frequency of hospitalization or ED visits.
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RATES OF DISCONTINUATION AMONG COMMONLY PRESCRIBED MEDICATIONS IN THE US
Vanelli MR, Pedan A, Messier D, Hoar J, Liu N, Kiarsis K Adheris, Inc, Burlington, MA, USA OBJECTIVES: To measure relative rates of discontinuation among commonly prescribed chronic disease medication classes under conditions of routine care. METHODS: De-identified pharmacy records for 1.99 million patients who received medication from retail pharmacy chains throughout the United States were used to select patients who obtained a fill between January 1, 2007 and January 30, 2007 for any of the following medication classes: antidepressants (n = 339,059); bisphosphonates (n = 120,098); cardiovascular agents (n = 622,947); glaucoma medications (n = 48,229); statins (n = 452,978); inhaled steroids (n = 95,900); insulins (n = 66,637); and oral antidiabetic agents (n = 248,280). The primary outcome measure was the median time-to-discontinuation (TD50). Kaplan-Meier analysis was used to estimate the risk of discontinuation over the subsequent 360 days for both "inexperienced" and "experienced" groups of patients. Inexperienced patients were defined as those who had not been dispensed an in-class medication in the prior 180 days; experienced patients were those who had been. Discontinuation was defined as being 30 days late for a scheduled refill. Patients switched to an in-class medication were considered to have continued therapy. RESULTS: Median days to discontinuation (TD50) among patients who had not filled a prescription for an in-class medication in the prior 180 days were: inhaled steroids Abstracts A451
